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RESUMEN 
El objetivo del estudio fue caracterizar los 
mecanismos de daño celular implicado en 
la fisiopatología de la citotoxicidad de la 
polimixina B en las células tubulares proxi-
males (LLC-PK1) y discutir las propuestas 
de intervención de enfermería para identi-
ficar a los pacientes de riesgo y considerar 
la prevención o el tratamiento de la lesión 
renal aguda nefrotóxica. Corresponde a un 
estudio experimental cuantitativo in vitro, 
en el cual las células fueron expuestas a sul-
fato de polimixina B. La viabilidad celular se 
determinó por exclusión de los colorantes 
fluorescentes y el método morfológico con 
la visualización de cuerpos apoptóticos a la 
microscopía de fluorescencia. Las células 
expuestas a polimixina B demostraron re-
ducción de la viabilidad, aumento de célu-
las apoptóticas y mayor concentración de 
la enzima lactato deshidrogenasa. La admi-
nistración de polimixina B in vitro  demos-
tró la necesidad de realizar acciones en la 
práctica clínica para minimizar los efectos 
adversos como la nefrotoxicidad.  
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RESUMO 
O objetivo do estudo foi caracterizar os 
mecanismos de lesão celular envolvidos 
na fisiopatologia da citotoxicidade da po-
limixina B em células tubulares proximais 
(LLC-PK1) e discutir as proposições de in-
tervenção do enfermeiro para identificar 
os pacientes de risco e considerar a pre-
venção ou o tratamento para lesão renal 
nefrotóxica. Estudo experimental in vitro, 
onde as células foram expostas ao sulfato 
de polimixina B. A viabilidade celular foi 
determinada pela exclusão dos corantes 
fluorescentes e o método morfológico com 
visualização de corpos apoptóticos à mi-
croscopia de fluorescência. As células ex-
postas à polimixina B apresentaram redu-
ção de viabilidade, aumento do número de 
células em apoptose e maior concentração 
da enzima desidrogenase láctea. A admi-
nistração de polimixina B in vitro demons-
trou a necessidade de ações na prática 
clínica para minimizar os efeitos adversos 
como a nefrotoxicidade.
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ABSTRACT 
The aim of the study was to characterize 
the cell damage mechanisms involved 
in the pathophysiology of cytotoxicity 
of polymyxin B in proximal tubular cells 
(LLC - PK1) and discuss about the nurses 
interventions to identify at risk patients 
and consider prevention or treatment of 
nephrotoxicity acute kidney injury. This is 
a quantitative experimental in vitro study, 
in which the cells were exposed to 375μM 
polymyxin B sulfate concentration. Cell vi-
ability was determined by exclusion of flu-
orescent dyes and morphological method 
with visualization of apoptotic bodies for 
fluorescence microscopy. Cells exposed 
to polymyxin B showed reduced viability, 
increased number of apoptotic cells and 
a higher concentration of the enzyme lac-
tate dehydrogenase. The administration 
of polymyxin B in vitro showed the need 
for actions to minimize adverse effects 
such as nephrotoxicity.
 
DESCRIPTORS
Polymyxin B
Anti-bacterial agents
Acute kidney injury
LLC-PK1 cells
Nursing care
Nephrotoxicity of polymyxin B: 
experimental study in cells and 
implications for nursing practice*
O
r
ig
in
a
l a
r
t
ic
l
e
Luciana Barros de Moura Neiva1, Fernanda Teixeira Borges2, Mirian Watanabe1, Edson de 
Andrade Pessoa3, Dulce Aparecida Barbosa4, Maria de Fatima Fernandes Vattimo5
NEFROTOXICIDADE DA POLIMIXINA B: ESTUDO EXPERIMENTAL EM CÉLULAS E 
IMPLICAÇÕES PARA A PRÁTICA DE ENFERMAGEM
LA NEFROTOXICIDAD DE POLIMIXINA B: ESTUDIO EXPERIMENTAL EN LAS CÉLULAS 
Y IMPLICACIONES PARA LA PRÁCTICA DE ENFERMERÍA
* Extracted from the thesis “Toxicity of polymyxin B in LLC-PK1 cells and the heme oxygenase-1 enzyme”, School of Nursing, Universidade de São Paulo, 
2008.  1 PhD at the School of Nursing, Universidade de São Paulo, São Paulo, SP, Brazil.  2 PhD at the Department of Nephrology, Universidade Federal de 
São Paulo, São Paulo, SP, Brazil 3 MSc at the Department of Nephrology, Universidade Federal de São Paulo, São Paulo, SP, Brazil. 4 Associate Professor, 
Department of Clinical and Surgical Nursing, Escola Paulista de Enfermagem, Universidade Federal de São Paulo, São Paulo, SP, Brazil. 5 Associate 
Professor, Department of Medical-Surgical Nursing, School of Nursing, Universidade de São Paulo, São Paulo, SP, Brazil. nephron@usp.br
Received: 12/20/2013
Approved: 02/20/2014
DOI: 10.1590/S0080-623420140000200011
Português / Inglês
www.scielo.br/reeusp
270 Rev Esc Enferm USP2014; 48(2):269-73www.ee.usp.br/reeusp/
Nephrotoxicity of polymyxin B: experimental study in 
cells and implications for nursing practice
Neiva LBM, Borges FT, Watanabe M, Pessoa EA, Barbosa DA, 
Vattimo MFF
INTRODUCTION
The hospital acute kidney injury (AKI) is of multifacto-
rial causes, and recent epidemiological studies link the 
nephrotoxic drugs with 19-25% of cases of AKI(1-2). The 
nephrotoxins are the second most frequent cause(2). An-
timicrobial agents such as aminoglycosides, amphotericin 
B, acyclovir, pentamidine, foscarnet, and chemotherapeu-
tic agents such as ifosfamide and cisplatin are toxic to the 
renal tubule(2-3). Among these frequently used substances 
in patients in intensive care units, are the polymyxins, 
which have a great nephrotoxic potential.
The polymyxin B (PmB) provides an effective and rapid 
bactericidal activity for a variety of Gram-negative bac-
teria such as Escherichia coli, Klebsiella pneumoniae and 
Pseudomonas aeruginosa. It is quite effective in the treat-
ment of sepsis, meningitis, urinary tract infection, skin 
and eye infections.
Prior to the appearance of new aminoglycosides, 
penicillins and cephalosporins, the PmB was the drug of 
choice for the treatment of Pseudomonas aeruginosa. It 
is currently reserved for the treatment of multiresistant 
bacteria to other antibiotics(4-6).
PmB sulfate or Aerosporin, is a cyclic cationic deca-
peptide with active surface that fits into the bacterial cell 
membrane, settling to lipid A, rendering ineffective its os-
motic barrier, which leads to loss of cell contents (amino 
acids, purines, pyrimidines and dilution of substrates for 
phenomena of synthesis) and bacterial cell death(4,6).
PmB is excreted mainly by the kidneys, and high con-
centrations of the drug in the body promote disruption 
of plasma membrane and increased permeability to cat-
ions, which results in swelling and lysis. This process in-
volves a mechanism of oxidative damage, alteration in 
mitochondrial apoptosis and necrosis of proximal tubule 
cells(2,7), culminating in renal dysfunction, characterized 
by imbalance of water and electrolytes and reduced ex-
cretion of nitrogenous products of metabolism such as 
urea and creatinine.
It is noteworthy that the successful prevention of 
AKI requires knowledge of the pathogenic mechanisms 
involved, the identification of individual risk factors and 
early measures associated with surveillance and interven-
tion. It is inserted in this context the stimulus to models of 
research about the cellular changes involved in functional 
disorder precipitated by nephrotoxins.
This study, supported by experimental research, can 
bring important contribution to the clinical area and al-
low early clinical reasoning, from the findings in studies 
with cells that guide the prevention or early treatment of 
patients with AKI. The objectives of the study are to char-
acterize the mechanisms of cell damage involved in the 
pathophysiology of cytotoxicity of PmB in proximal tubu-
lar cells (LLC-PK1), discuss the intervention proposals of 
nurses to identify patients at risk and to consider preven-
tion or treatment for nephrotoxic AKI.
METHOD
Experimental in vitro study carried out in the Labora-
tory of Experimental Animal Model of the School of Nurs-
ing of the Universidade de São Paulo (LEMA - EEUSP) and 
the Laboratory of Cellular and Molecular Biology of the 
Nephrology Department of the Universidade Federal de 
São Paulo (UNIFESP).
Immortalized LLC-PK1 cells, a proximal tubular epithe-
lial pig line, obtained from the American Type Culture Col-
lection (ATCC) were used. These cells were extracted from 
the Hampshire pig and have morphological characteristics 
of renal epithelium as apical microvilli, tight junctions and 
basolateral membrane.
The LLC-PK1 were grown in culture bottles of 25 cm2, 
75cm2 or multiwell six-well plates, according to the experi-
mental protocol in Dulbecco’s Modified Eagle’s Medium 
(DMEM), supplemented with fetal bovine serum (FBS 5% v 
/ v), NaHCO
3
 2.0 g/L, HEPES 2.6 g/L, penicillin 10,000 IU/L, 
streptomycin 50 mg/L and neomycin 100 mg/L and kept 
in the incubator at 37°C with 95% air and 5 % CO
2
. Upon 
reaching 80% confluence, cells were detached from the 
flask by trypsinization and the trypsin activity neutralized 
with DMEM containing FBS. Cells were used for mainte-
nance of the cultures or for conducting the experimental 
protocols, with each protocol repeated at least four times. 
Cell stocks were frozen at passage seven for maintaining 
uniformity in the experiments.
LLC-PK1 cells were divided in two groups, as follows: 
Control (CTL), with cells maintained in DMEM 5% and 
PmB with cells exposed to concentration of 375mM of 
sulfate of PmB.
Cell viability was determined by exclusion of fluores-
cent dyes acridine orange and ethidium bromide (Sig-
ma)(8). In order to read viability were used only 10mL of 
the suspension of trypsinized cells that were mixed with 
0.3 mL of the solution of acridine orange dye and ethid-
ium bromide (100mg/ml) in a ratio v:v (1:1). The method 
of viable cell count is based on the selective uptake of 
the mentioned dyes, which is dependent on the integ-
rity of the plasma membrane. Ethidium bromide passes 
through the intact membrane, by binding to cellular DNA 
and emitting green fluorescence (460nm excitation and 
650 nm emission) indicating cells are viable. The acridine 
orange stains RNA but it does not pass through intact 
membrane, is captured only by cells whose membrane 
is damaged and fluoresces orange-red (510nm excitation 
and 595nm emission), showing which cells are not vi-
able. At the end, at least 200 cells were counted for each 
representative group through a fluorescence microscope 
(magnification 40x and 200). The results were expressed 
as percentage of viable cells.
271Nephrotoxicity of polymyxin B: experimental study in cells and implications for nursing practiceNeiva LBM, Borges FT, Watanabe M, Pessoa EA, Barbosa DA, 
Vattimo MFF
Rev Esc Enferm USP
2014; 48(2):269-73
www.ee.usp.br/reeusp/
The assessment of apoptosis is the morphological 
method, quantitative Hoechst 33342 [Bisbenzimide HOE 
33342 (2’-[4-etoxifenil]-5-[4-metil-1-piperazinil]-2,5’-bi-
1H-benzimidazol tricloridrato)], which is a specific dye 
for adenine-thymine. This dye is easily absorbed by the 
cell, staining the DNA, chromosomes and the nucleus, 
enabling the visualization of apoptotic bodies for fluores-
cence microscopy in intense blue coloration.
For evaluation of apoptosis it was prepared a solu-
tion 100mg/mL Hoescht 33342 dye in PBS (Phosphate-
buffered saline). The cells were subjected to the same de-
scribed preparation for viability assessment, to obtain the 
cell pellet. On the blade 5 mL was pipetted on the slide 
of Hoechst 33342 added to 5 mL of the cell suspension. 
The blade was stored for 10 minutes at room temperature 
and in the absence of light for chromatin staining(8). Then 
the procedure was the count of 100 to 200 cells for each 
group. Results were expressed as percentage of apoptotic 
cells compared to total cells.
The degree of cell damage was assessed by measure-
ment of lactate dehydrogenase (LDH) in the culture me-
dium and cell. The release of LDH enzyme that catalyzes 
the reduction of pyruvate to lactate was measured in the 
cells and culture medium. The relationship between the 
activity of extracellular LDH (culture medium) and total 
activity (intracellular and culture medium) established 
the degree of cell damage. The culture medium was as-
pirated and transferred to a conical tube, centrifuged 
at 2000 rpm for 4 minutes and the supernatant was 
removed for reading. The cells were washed with PBS 
twice and lysed with the detergent Triton X-100 1% for 
the concentration dosage of cellular LDH. The kinetic 
method was used, in which the conversion of pyruvate 
to lactate was observed for determining the amount of 
LDH. This reaction was performed with the LDH Kit Liqui-
form® and the reading of the Bio - 200. The results were 
presented as percentage of damaged cells. For the cal-
culation, the following formula was used: [culture me-
dium/(culture medium + cell number)] x 100%(8).
Statistical analysis
The applied statistical methodology consisted of analy-
sis of variance – ANOVA. When differences were detected, 
there were multiple comparisons by using the Bonferroni 
test and Tukey test. The descriptive statistics with p<0.05 
were considered significant. Data were defined as mean ± 
standard error and are shown in tables.
RESULTS
Figure 1 demonstrates a significant reduction in cell 
viability at the exposure dose of 375mM of PmB, which 
reflects its toxicity (CTL: 81±6% versus PmB: 41±2%; 
p<0.05). Inversely, this dose increased the number of 
apoptotic cells at 72 hours (CTL: 9±2% versus PmB: 
36±4%; p<0.05).
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Figure 1 - Viability and apoptosis of LLC-PK1 cells.
Table 1 shows the results of LDH release in LLC-PK1 
cells. Starting treatment with a dose of 375mM PmB there 
was significant increase in LDH release, compared to the 
control group (p<0.05). 
Table 1 - LDH release in LLC-PK1 cells.
Groups N LDH (%)
Control 8 1.77±0.17
Polymyxin B 8 22.66±1.77*
*p<0,05 versus Control. 
DISCUSSION
In vitro models that simulate PmB toxicity in renal cells 
are not common. Despite its known nephrotoxic poten-
tial, intra-hospital application has been frequent due to 
the presence of multiresistant microorganisms.
This study demonstrated that LLC-PK1 cells exposed 
to 375mM PmB showed reduction in cell viability. In renal 
cells, this cytotoxic dose of PmB may also determine the 
mechanism of renal tubular cell death.
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In response to cytotoxic events to the kidney, it is pos-
sible to recognize four basic directions: the cells may enter 
necrosis or apoptosis; can replicate and divide or may be 
indifferent to stress(9).
In clinical practice, AKI is conventionally known as acute 
tubular necrosis (ATN). Experimental studies have shown that 
the straight portion of the proximal tubule (S3 segment) is 
the most vulnerable to ischemic or nephrotoxic injury. These 
tubular cells lose their brush border and undergo extensive 
cell necrosis. Despite the frequent use of the term necrosis, 
apoptosis, which is another mechanism of cell death, is also 
present in ischemic and nephrotoxic injuries(2).
It is noteworthy that the cells exposed to PmB showed 
an increase in the number of cells undergoing apoptosis. The 
cell necrosis was observed indirectly through the release of 
LDH into the extracellular medium. The LDH, a cytosolic en-
zyme, is released by rupturing the cell membrane, indicating 
cell death by necrosis. Apoptosis is a rapid, synchronized pro-
cess that culminates in the nuclear and cellular fragmenta-
tion in apoptotic vesicles. Unlike necrosis, there is no release 
of cellular contents into the extracellular medium, charac-
terized by the absence of inflammation around the dead 
cell. Necrosis is an irreversible degenerative phenomenon, 
caused by intense aggression, i.e., high doses of nephrotoxic 
drugs such as PmB, chemotherapy or iodinated contrast me-
dia, explaining that the severity of aggression seems to be 
the determining factor in the mechanism of cell death.
The onset of AKI secondary to the use of PmB often oc-
curs a few days after the start of drug therapy in hospitalized 
patients. The toxicity of this substance is dose and time de-
pendent, considering it is primarily excreted by the kidneys. 
An in vitro study demonstrated PmB injury in LLC-PK1 cells 
with the evolution of time and dose(10).
This study used the in vitro model of transposition of 
clinical scenarios for the lab bench, in an attempt to isolate 
non-modifiable factors in humans, but that in the cellular 
medium can be differentiated and identified. A current ap-
proach allows the introduction of the three phases of trans-
lational research, the ‘3 Bs’ (Bench, Bedside and Back again), 
a dynamic and feedback process(11).
The first pillar  –  bench - is formed by the basic research 
in vivo or in vitro, which is the basis for the exercise of prac-
tical reasoning and establishment of new clinical guide-
lines(11-12). In other words, its results applied to nursing prac-
tice can determine care activities that are supported by the 
pharmacological knowledge of PmB and the pathophysiolo-
gy of toxic AKI, characterizing the transposition of basic ex-
perimental research to healthcare practice(13). The second 
pillar – bedside - encompasses studies that evaluate the ef-
fectiveness, acceptability and cost/benefit of interventions 
of clinical sciences(11-12), exemplified by randomized stud-
ies that evaluate the effectiveness of preventive measures 
undertaken in patients who have risk factors for AKI dur-
ing the administration of nephrotoxic drugs(14-15). And the 
last pillar – back again – adds the necessary information to 
convert treatments and prevention strategies in foundation 
for evidence-based health policies(11,13). 
Implications for practice
The nephrotoxic AKI is an iatrogenic disease caused by 
the administration of drugs or contrasts for image diagnosis 
in patients with risk factors or situations(16-17). Clinical features 
include oliguria or anuria, elevation of serum creatinine and 
electrolyte disturbances(17). The incidence of AKI may be as-
sociated with periods of prolonged hospitalization resulting 
in increased morbidity and mortality and, consequently, in-
crease of hospital costs of these patients(18).
In this context, stands out the role of nurses in moni-
toring, analysis and interpretation of laboratory exams and 
identification of risk factors associated with the development 
of AKI. The efficiency of nursing care is determined by means 
of early identification of AKI, or rather the recognition of re-
lated factors or defining characteristics for PmB nephrotoxic-
ity that allow to establish the first guidelines(19-20).
The first strategies are the correct completion of the 
nursing history and the physical examination to identify risk 
factors associated with nephrotoxic drug-induced AKI. The 
main feature of the AKI is the reduction of glomerular filtra-
tion rate, which results in accumulation of nitrogenous prod-
ucts – urea and serum creatinine – a medical condition called 
azotemia(16). Patients with minimal reduction in filtration rate 
have risk factors for AKI(7).
Nurses should also consider the continued use of medi-
cations and especially those with nephrotoxic potential. 
A classic example are the non-steroidal anti-inflammatory 
drugs and the inhibitors of angiotensin converting enzyme 
(ACE), which reduce renal perfusion and favor the mecha-
nism of renal injury(21). The same perception and attention 
should be given to the indiscriminate and more recent use of 
vitamin supplements and herbal medications, because many 
patients do not consider this category as drugs and are un-
aware of their contribution to the development of AKI(16).
Toxic AKI involves numerous intrinsic factors, some non-
modifiable, such as high age, gender, hypertension, chronic 
renal failure, congestive heart failure, multiple myeloma and 
modifiable factors such as dehydration, medication dosage, 
hypotension, concomitant use of nephrotoxic drugs, shock 
and sepsis(7,14,21).
The preparation of a plan of care for patients in use of 
nephrotoxic drugs involves mainly the action of nurses in 
modifiable factors. During hospitalization of patients, epi-
sodes of hypotension should be monitored and avoided, 
since the reduction of blood perfusion can lead to kidney 
damage. The volemic status of the patient should also be 
carefully controlled by means of urinary flow. Hypovolemia is 
directly associated with toxic AKI(16,21-22).
Another item to consider is the patient´s prescrip-
tion, where various pharmacological agents are admin-
istered for the treatment of various pathologies. The 
273Nephrotoxicity of polymyxin B: experimental study in cells and implications for nursing practiceNeiva LBM, Borges FT, Watanabe M, Pessoa EA, Barbosa DA, 
Vattimo MFF
Rev Esc Enferm USP
2014; 48(2):269-73
www.ee.usp.br/reeusp/
adjustment of the drug dose in relation to body weight 
and the ability of excretion should be done especially 
during the administration of nephrotoxic drugs. The ad-
justment in the dose of the drug is needed to ensure that 
the correct therapeutic range is reached and the incor-
rect dosage or maintenance of high doses increases the 
incidence of AKI(16,23). 
During the administration of PmB it is important that 
the nurses acknowledge the major risk factors associated 
with patients and apply all the available mechanisms of re-
nal protection for maintaining the volume, care in the use of 
other nephrotoxic medications and close monitoring of renal 
function, with laboratory control of creatinine, urea, electro-
lytes and urine flow(16).
CONCLUSION
The cytotoxicity of PmB was determined by reduction 
of viability, increase of cells in apoptosis and release of 
the lactate dehydrogenase enzyme, signaling to cell dam-
age by necrosis. The administration of PmB involves ac-
tions to minimize adverse effects, in which the main focus 
is nephrotoxicity for identifying risks and the mechanism 
of renal protection.
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